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The influence of alloxan-induced diabetes on the reactivity of rabbit basilar artery to endothelin-1 was examined. Endothelin-1 induced
concentration-dependent contraction of basilar arteries that was higher in diabetic than in control rabbits. Endothelium removal produced a
higher enhancement of the endothelin-1-induced contraction in control than in diabetic rabbits. NG-nitro-L-arginine (L-NOArg) enhanced the
maximal contraction induced by endothelin-1 in control rabbits and potentiated this response in diabetic rabbits. Endothelin ETA receptor
antagonist, cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) (BQ-123), inhibited endothelin-1-induced contraction in both rabbit groups. Endothelin ETB
receptor antagonist, 2,6-Dimethylpiperidinecarbonyl-g-Methyl-Leu-Nin-(Methoxycarbonyl)-D-Trp-D-Nle (BQ-788), enhanced endothelin-1-
induced contraction in control rabbits and decreased the potency of endothelin-1 in diabetic rabbits. Sodium nitroprusside-induced relaxation
of basilar arteries was lower in diabetic than in control rabbits. These results suggest that mechanisms underlying rabbit basilar artery
hyperreactivity to endothelin-1 include decreased endothelial modulation of endothelin-1-induced contraction, with impaired endothelial
endothelin ETB receptor activity; decreased sensitivity to nitric oxide (NO) in vascular smooth muscle; and enhanced participation of
muscular endothelin ETA and ETB receptors.
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Several studies have demonstrated the correlation be-
tween diabetes and cerebrovascular diseases. Diabetic
patients have increased susceptibility to hypoxic and ische-
mic injury in cerebral vessels (Mankovsky et al., 1996).
Diabetes increases the risk of stroke and stroke mortality, and
decreases recovery after stroke (Lukovits et al., 1999).
Because of the rising prevalence of diabetes mellitus, its
role as a risk factor for stroke and other vascular diseases
may take increasing importance in the coming years (Luko-
vits et al., 1999).
Endothelin-1 could play a role in the pathophysiology of
diabetic complications. Diabetes increases plasma endothe-
lin-1 levels (Schneider et al., 2002) and basal endothelin-10014-2999/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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Also, endothelin-1 has a role in the pathophysiology of
cerebral ischemia. It has been shown that endothelin-1
concentration is increased in plasma of patients with acute
ischemic stroke (Estrada et al., 1994). Moreover, the use of
endothelin-1 receptor antagonists increases cerebral perfu-
sion and reduces ischemic damage in focal cerebral ische-
mia (Barone et al., 1995). The link between endothelin-1,
diabetes and ischemic stroke has not yet been sufficiently
investigated. The hyperglycemia of diabetes induces a
‘‘pseudohypoxic’’ state in vascular tissue (Williamson et
al., 1993). Hypoxia enhances the contractile actions of
endothelin-1 (Douglas et al., 1991). Thus, it is possible that
the diabetic state potentiates this effect, contributing to the
greater susceptibility to ischemic damage in diabetic
patients (Hopfner and Gopalakrishnan, 1999).
Endothelial dysfunction could explain, at least partially,
the altered response to several vasoconstrictors and vaso-
dilators observed in diabetes. Recently, it has been sug-
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function in type 2 diabetic subjects (Mather et al., 2002).
Nevertheless, it still remains a task to elucidate the mech-
anisms by which the impaired endothelial regulation pro-
duces an abnormal vascular reactivity in diabetes (De Vriese
et al., 2000).
We have previously described the existence of hyper-
reactivity to endothelin-1 of cerebral arteries after cere-
bral ischemia (Salom et al., 2000) and subarachnoid
haemorrhage (Alabadı´ et al., 1997). On the other hand,
we have also reported alterations in the vascular re-
sponse of diabetic animals to 5-hydroxytryptamine (Mi-
randa et al., 2000a, 2002) and acetylcholine (Miranda et
al., 2000b; Alabadı´ et al., 2001). The aim of the present
study was to analyse the influence of alloxan-induced
diabetes on the reactivity of the rabbit basilar artery to
endothelin-1, including attention to endothelin-1 receptors
and the endothelial modulatory mechanisms regulating
this response.2. Materials and methods
Forty-nine male New Zealand white rabbits were used in
the present study. Animals were randomly divided into two
experimental groups: 25 in the control group and 24 for
induction of experimental diabetes. Experiments were per-
formed according to the guidelines from the Council of the
European Union (86/609/EEC, Article 5, Appendix II),
promulgated by the Spanish legislation on March 14,
1988 (R.D. 223/1988).
2.1. Induction of diabetes and control animals
For induction of experimental diabetes, the rabbits
(n = 24, body weight 2.63F 0.05 kg, glycemia 5.8F 0.2
mM) were previously sedated with intramuscular 40 mg of
ketamine (KetolarR). Diabetes was induced by injecting
alloxan (100 mg kg 1) into the lateral ear vein. Alloxan is a
diabetogenic agent which induces in the animal a syndrome
resembling Type-I diabetes mellitus and is commonly used
as a valid experimental model of diabetes in the rabbit
(Chan et al., 2000). To prevent hypoglycemia, 10 ml of 5%
glucose was injected (i.v.) after the alloxan and drinking
water was supplemented with 10% glucose for the first 24
h after the alloxan injection. Thereafter, the animals were
maintained on tap water and regular food ad libitum for 6
weeks. At this time, rabbits (diabetic rabbits) showed a
significant increase in serum glucose (21.1F 0.6 mM) and
their body weight (3.01F 0.07 kg) increased slightly. A
second group of rabbits (n= 25, body weight 2.57F 0.05
kg, glycemia 5.7F 0.1 mM) was maintained under the same
conditions for the same time period to serve as age-matched
controls (henceforth ‘‘control rabbits’’). In these rabbits
(control rabbits), after 6 weeks, the values for glycemia
were similar (6.0F 0.2 mM) and the body weight hadincreased to 3.54F 0.06 kg. This body weight increase
was significantly higher than that observed in the diabetic
rabbits.
2.2. Isometric tension recording
Six weeks after diabetes induction, the diabetic and the
age-matched control rabbits were anaesthetised with sodi-
um thiopental (sodium pentothal, 2% i.v.) and killed by
injection of potassium chloride (10 mEq, 0.5 ml kg 1,
i.v.) into the lateral ear vein. The entire brain, including
the brainstem, was removed, and the basilar artery was
dissected free and cut into cylindrical segments measuring
3 mm in length. For isometric tension recording, the
segments were mounted in an organ bath using tungsten
wires (89 Am in diameter). Two pins were introduced
through the arterial lumen. One pin was fixed to a
stationary support, while the other pin was connected to
a strain gauge for isometric tension recording. The organ
bath contained 5 ml of Ringer–Locke solution that was
bubbled continuously with 95% O2 and 5% CO2 to
provide a pH of 7.3–7.4. Temperature was kept at 37
jC. A resting tension of 0.5 g was applied to the arterial
segments, which were allowed to equilibrate for a period
of 60–90 min before the start of the experiments. Tension
was readjusted when necessary and the bath fluid was
changed every 15 min. After this period of equilibration,
the reactivity of the arterial segments from the control and
diabetic groups was checked by depolarisation with 50
mM KCl. There were no significant differences (unpaired
Student’s t test) in the response to KCl between arteries
from control (1216F 42 mg) and diabetic (1200F 53 mg)
rabbits.
2.3. Concentration–response curves
The experiments were carried out with basilar arteries
from both control and diabetic rabbits. Concentration–
response curves for endothelin-1 (10-12 to 3 10 8 M)
were obtained by its cumulative addition to the organ bath.
To assess the influence of the endothelium on the effect of
endothelin-1, concentration–response curves were obtained
from arteries in which the endothelium had been removed
by gentle rubbing of the intimal surface with a scored
stainless-steel rod (rubbed arteries). The absence of endo-
thelium was tested for by silver staining and by checking the
absence of relaxant response to acetylcholine. To study the
participation of nitric oxide (NO) in the response of basilar
arteries to endothelin-1, the concentration–response curves
to this peptide were obtained after incubation (20 min) of
the arteries with the inhibitor of NO synthase, NG-nitro-L-
arginine (L-NOArg, 10 4 M). The possibility that some
arachidonic acid derivative could modulate the arterial
response to endothelin-1 was examined by obtaining con-
centration–response curves for endothelin-1 after incuba-
tion (20 min) of the arteries with indomethacin (10 5 M),
Fig. 1. Concentration–response contraction curves for endothelin-1 in
basilar arteries isolated from control and diabetic rabbits. Contraction
values are expressed as percentages of the previous depolarisation induced
by 50 mM KCl and represent meansF S.E.M.
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tion of specific endothelin ETA receptors, concentration–
response curves for endothelin-1 were obtained in the
presence (20 min of incubation) of the selective endothelin
ETA receptor antagonist, cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)
(BQ-123, 10 6 M). To study the participation of specific
endothelin ETB receptors in this response, concentration–
response curves for endothelin-1 were obtained in the
presence (20 min of incubation) of the selective endothelin
ETB receptor antagonist, 2,6-Dimethylpiperidinecarbonyl-
g-Methyl-Leu-Nin-(Methoxycarbonyl)-D-Trp-D-Nle (BQ-
788, 10 6 M). Finally, to check the possibility that endo-
thelin ETB receptors located in the smooth muscle cells
participate in the response of the basilar artery to endothe-
lin-1, concentration–response curves for endothelin-1 were
obtained in rubbed arteries incubated (20 min) with BQ-788
(10 6 M).
To detect possible changes in the sensitivity of the
vascular smooth muscle cells to NO, concentration–re-
sponse curves for sodium nitroprusside (10 9–10 4 M)
were obtained cumulatively with basilar arteries from both
control and diabetic rabbits, previously precontracted with
UTP (10 4 M).
2.4. Drugs and solutions
Alloxan, BQ-123, BQ-788, endothelin-1, indomethacin
and UTP were obtained from Sigma-Aldrich Quı´mica. L-
NOArg was obtained from Peptide Institute and sodium
nitroprusside from RBI. Alloxan was dissolved in saline
solution. BQ-123, BQ-788, UTP and L-NOArg were dis-
solved in twice-distilled water and diluted with saline
solution. The L-NOArg solution required sonication to
dissolve completely. Endothelin-1 was dissolved in 0.1%
aqueous acetic acid and diluted in a phosphate-buffered
saline solution with 0.05% bovine serum albumin, fraction
V (Sigma). Indomethacin was dissolved in ethanol and
diluted in saline solution. Sodium nitroprusside was dis-
solved and diluted in saline solution. Care was taken to
protect sodium nitroprusside solutions from light due to its
light sensitivity. The composition of the Ringer–Locke
solution was (mM): NaCl, 120; KCl, 5.4; CaCl2, 2.2;
MgCl2, 1.0; NaHCO3, 25 and glucose, 5.6. To prepare
the KCl-depolarising solution, NaCl was replaced by an
equimolar amount of KCl in the normal Ringer–Locke
solution.
2.5. Statistical analysis
Comparisons of body weight and glycemia between
control and diabetic rabbits were made by using an unpaired
Student’s t test. For the concentration–response curves,
contraction values were expressed as percentages of the
previous depolarisation induced by 50 mM KCl, and relax-
ation values as percentages of the active tone induced by
UTP 10 4 M. For each concentration–response curve, themaximum effect (Emax) and the concentration of drug which
produced half of Emax (EC50) were calculated. Maximum
effects were expressed as meansF S.E.M. and EC50 as the
geometric mean with its confidence limits (95%) for repeat-
ed experiments. Statistical comparisons of Emax and  log
EC50 (pD2) values between arteries from control rabbits and
arteries from diabetic rabbits subjected to the same exper-
imental treatment were achieved by using an unpaired
Student’s t test. Comparisons between the values of Emax
and pD2 for the concentration–response curves for endo-
thelin-1 obtained with the different treatments of arteries
from control rabbits were made using an analysis of
variance (ANOVA) followed by the Newman–Keuls test.
The same tests were used to compare Emax and pD2 values
of the curves obtained with the different treatments of
arteries from diabetic rabbits. A probability value of less
than 5% was considered significant.3. Results
3.1. Concentration–response curves for endothelin-1
Cummulative addition of endothelin-1 (10 12 to
3 10 8 M) produced a concentration-dependent contrac-
tion of the basilar artery from either control or diabetic
rabbits (Fig. 1). In arteries from diabetic rabbits, the Emax of
the concentration–response curve for endothelin-1 was
significantly higher than that obtained with arteries from
control rabbits, while there were no significant differences
between the EC50 values (Fig. 1; Table 1).
Endothelium removal displaced to the left (significantly
lower EC50) the concentration–response curve for endothe-
Fig. 2. Concentration–response contraction curves for endothelin-1 in
basilar arteries isolated from control rabbits under the following
experimental conditions: control, without endothelium (rubbed), incubation
with L-NOArg (10 4 M) and incubation with indomethacin (10 5 M).
Contraction values are expressed as percentages of the previous
depolarisation induced by 50 mM KCl and represent meansF S.E.M.
Fig. 3. Concentration–response contraction curves for endothelin-1 in
basilar arteries isolated from diabetic rabbits under the following
experimental conditions: control, without endothelium (rubbed), incubation
with L-NOArg (10 4 M) and incubation with indomethacin (10 5 M).
Contraction values are expressed as percentages of the previous
depolarisation induced by 50 mM KCl and represent meansF S.E.M.
Table 1
Half-maximal effective concentration (EC50) and maximum effect (Emax)
values for concentration– response curves for endothelin-1 in rabbit basilar
artery
EC50 (M) Emax (%) n
Control rabbits
Control 2.3 (1.5–3.5) 10 10 100F 3 17
Rubbed 2.6 (1.7–4.2) 10 11a 125F 5a 11
L-NOArg (10 4 M) 1.1 (0.8–1.7) 10 10 119F 6a 12
Indomethacin
(10 5 M)
6.8 (5.6–8.1) 10 10 110F 6 12
BQ-123 (10 6 M) 4.0 (3.1–5.1) 10 9a 111F 5 11
BQ-788 (10 6 M) 2.3 (1.4–3.8) 10 10 126F 6a 11
Rubbed +BQ-788 1.4 (1.1–1.7) 10 10b 125F 10a 9
(10 6 M)
Diabetic rabbits
Control 1.4 (0.9–2.2) 10 10 114F 4c 18
Rubbed 8.1 (6.2–10.7) 10 12ac 116F 7 10
L-NOArg (10 4 M) 1.5 (0.8–2.9) 10 11ac 124F 11 10
Indomethacin
(10 5 M)
2.0 (1.3–3.3) 10 10c 113F 5 13
BQ-123 (10 6 M) 3.2 (2.4–4.1) 10 9a 120F 6 11
BQ-788 (10 6 M) 1.1 (0.8–1.7) 10 9ac 123F 7 10
Rubbed +BQ-788
(10 6 M)
4.1 (3.4–4.9) 10 10bc 125F 5 9
Emax values are expressed as percentages of a previous depolarisation with
KCl 50 mM. EC50 values are means and confidence limits; Emax values are
meansF S.E.M.
L-NOArg: NG-nitro-L-arginine.
a Significantly different from corresponding control value, P < 0.05.
b Significantly different from corresponding rubbed value, P< 0.05.
c Significantly different from corresponding value for control rabbits,
P < 0.05.
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also increased significantly the Emax of the concentration–
response curve for endothelin-1 obtained with arteries from
control rabbits (Figs. 2 and 3; Table 1). Moreover, in
endothelium-denuded arteries from diabetic rabbits, the
EC50 value of the concentration–response curve for endo-
thelin-1 was significantly lower than that obtained in
arterial segments without endothelium from control rabbits
(Table 1).
In basilar arteries from control rabbits, incubation with L-
NOArg (10 4 M) significantly enhanced the maximal
contraction of the concentration–response curve for endo-
thelin-1, without significantly changing the EC50 value (Fig.
2; Table 1). However, incubation of basilar arteries from
diabetic rabbits with the same inhibitor of NO synthase, L-
NOArg (10 4 M), did not significantly modify the Emax, but
significantly decreased the EC50 value of the concentra-
tion–response curves for endothelin-1 (Fig. 3; Table 1).
Moreover, comparison showed that the endothelin-1-in-
duced contraction in arterial segments incubated with L-
NOArg had an EC50 value of the concentration–response
curve significantly lower in arteries from diabetic rabbits
than that obtained in arteries from control rabbits (Table 1).
Incubation of basilar arteries from either control and
diabetic rabbits with indomethacin (10 5 M) did not sig-nificantly modify the contractile response to endothelin-1
(Figs. 2 and 3; Table 1).
The incubation of basilar arteries from either control or
diabetic rabbits with the antagonist of the endothelin ETA
receptors, BQ-123 (10 6 M), significantly increased the
EC50 value (displaced to the right) of the concentration–
Fig. 5. Concentration–response contraction curves for endothelin-1 in
basilar arteries isolated from diabetic rabbits under the following
experimental conditions: control, without endothelium (rubbed), incubation
with BQ-123 (10 6 M), incubation with BQ-788 (10 6 M) and incubation
of rubbed arteries with BQ-788 (10 6 M). Contraction values are expressed
as percentages of the previous depolarisation induced by 50 mM KCl and
represent meansF S.E.M.
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Emax value (Figs. 4 and 5; Table 1).
Incubation of basilar arteries from control rabbits with the
antagonist of the endothelin ETB receptors, BQ-788 (10
 6
M), significantly increased the Emax value of the concentra-
tion–response curve for endothelin-1, without modifying
the EC50 value (Fig. 4; Table 1). However, for basilar
arteries from diabetic rabbits, preincubation with BQ-788
did not significantly modify the Emax value, but significantly
increased the EC50 value (displaced to the right) of the
concentration–response curve for endothelin-1 (Fig. 5;
Table 1). In addition, comparing the endothelin-1-induced
contraction in arterial segments incubated with BQ-788, the
EC50 value for the concentration–response curve was sig-
nificantly higher with arteries from diabetic rabbits than that
obtained with arteries from control rabbits (Table 1).
The incubation of rubbed basilar arteries with BQ-788
(10 6 M) significantly increased the EC50 (displaced to the
right) of the concentration–response curve for endothelin-1
as compared to the corresponding curve obtained with
rubbed arteries in the absence of BQ-788 from either control
(Fig. 4; Table 1) or diabetic (Fig. 5; Table 1) rabbits.
Moreover, the EC50 value for the concentration–response
curve for endothelin-1 obtained in rubbed arteries incubated
with BQ-788 (10 6 M) from diabetic rabbits was signifi-
cantly higher than that obtained with the corresponding
arteries from control rabbits (Table 1).
Table 1 summarises the Emax and EC50 values of con-
centration–response curves for endothelin-1 under the dif-
ferent experimental conditions.Fig. 4. Concentration– response contraction curves for endothelin-1 in
basilar arteries isolated from control rabbits under the following
experimental conditions: control, without endothelium (rubbed), incubation
with BQ-123 (10 6 M), incubation with BQ-788 (10 6 M) and incubation
of rubbed arteries with BQ-788 (10 6 M). Contraction values are expressed
as percentages of the previous depolarisation induced by 50 mM KCl and
represent meansF S.E.M.3.2. Concentration–response curves for sodium
nitroprusside
Cummulative addition of sodium nitroprusside (10 9–
10 4 M) produced concentration-dependent relaxation of
isolated basilar arteries previously contracted with UTP
(10 4 M) from both control and diabetic rabbits (Fig. 6).
In basilar arteries from control rabbits, the EC50 value wasFig. 6. Concentration– response relaxant curves for sodium nitroprusside in
basilar arteries isolated from control and diabetic rabbits. Relaxation values
are expressed as percentages of the active tone induced by UTP 10 4 M
and represent meansF S.E.M.
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the active tone (n = 11). With arteries from diabetic rabbits,
the EC50 value of the curves for sodium nitroprusside was
5.0 (4.2–6.0) 10 7 M and the Emax value was 86F 3% of
the active tone (n = 8). Comparison of relaxations induced
by sodium nitroprusside in basilar arteries showed that, for
diabetic rabbits, the EC50 value was significantly higher and
the Emax value was significantly lower than was found for
arteries from control rabbits.
There were no significant differences in the UTP (10 4
M)-induced active tone between basilar arteries from control
(751F 84 mg, n = 11) and diabetic (634F 60 mg, n = 8)
rabbits.4. Discussion
The present study showed enhancement of the contractile
response of isolated rabbit basilar artery to endothelin-1 in
diabetes. An increased vascular response to endothelin-1 has
been reported in different pathophysiological conditions
such as cerebral ischemia (Salom et al., 2000), subarachnoid
hemorrhage (Alabadı´ et al., 1997) and hypertension (Car-
dillo et al., 1999). In diabetes, endothelin-1-induced con-
traction was enhanced in aorta (Hattori et al., 1999), and in
renal and mesenteric (Kiff et al., 1991) rat arteries. More
recently, an enhancement of the sensitivity to endothelin-1
in isolated subcutaneous resistance arteries of diabetic
patients (McIntyre et al., 2001) was observed. Moreover,
studies performed in vivo show an enhancement of the
reactivity to endogenous endothelin-1 in resistance vessels
of diabetic patients (Cardillo et al., 2002), and enhanced
response to the peptide in resistance arterioles of diabetic
hamsters (Mayhan et al., 1999). This cerebrovascular hy-
perreactivity to endothelin-1 could play a role in the
pathogenesis of cerebral ischemia of diabetic patients.
In contrast to our results, the response to endothelin-1 in
rat basilar artery in vivo was similar in control rats and in
diabetic rats 3–4 months after injection of streptozotocin
(Mayhan, 1998). Differences in the diabetes duration, ani-
mal species, in vivo vs. in vitro methodology and diabeto-
genic agent could explain this discrepancy.
The hyperreactivity to endothelin-1 is not the result of a
non-specific increase in the reactivity of the rabbit basilar
artery induced by diabetes, since we have observed that the
contractile response of basilar arteries to other vasoconstric-
tors such as UTP and 5-hydroxytryptamine (data not shown)
was similar in diabetic and in control rabbits.
In arteries from control rabbits, mechanical removal of
the endothelium increased the maximal contraction and
displaced to the left the concentration–response curve for
endothelin-1, indicating an inhibitory endothelial modula-
tion of the contractile action of this peptide. These results
are in accordance with results of previous work performed
with cerebral arteries of non-diabetic animals (Salom et al.,
1991; Petersson et al., 1997). In arteries from diabeticrabbits, endothelium denudation also displaced to the left
the concentration–response curve for endothelin-1, without
significant changes in the maximal contraction, suggesting a
lower modulatory role of endothelium in the diabetic state.
This fact could contribute to the hyperreactivity to endothe-
lin-1 observed in diabetic rabbits. Consistent with our
results, the endothelial modulation of the vascular responses
to several stimuli is impaired in aorta and carotid arteries of
gestational diabetic women (Hu et al., 1998) and in aorta
(Pagano et al., 1998) and renal artery (Costa e Forti and
Fonteles, 1998) of alloxan-induced diabetic rabbits.
The modulatory action of the endothelium could be
effected, at least partially, through the release of NO. In
control rabbits, incubation of the arterial segments with L-
NOArg, an inhibitor of the constitutive NO synthase,
significantly enhanced the maximal contraction induced
by endothelin-1, indicating an inhibitory role for NO in
the modulation of the contractile response of the basilar
artery to endothelin-1. This inhibitory role of NO in the
endothelin-1-induced vasoconstriction has been described
for the cerebrovascular bed (Alabadı´ et al., 1997). On the
other hand, incubation of basilar arteries from diabetic
rabbits with L-NOArg did not significantly modify the
maximal contraction but displaced to the left the concen-
tration–response curve for endothelin-1, suggesting that, in
diabetes, the inhibitory role of NO in the response of
basilar artery to endothelin-1 differs from that seen in
control rabbits. The alteration in the NO inhibitory role
could be related to changes in NO production and/or
sensitivity of vascular smooth muscle cells to NO induced
by diabetes. There is a report of a decreased NO production
in diabetes (Lagaud et al., 2001). In addition, our results for
the relaxation induced by the NO donor, sodium nitroprus-
side (lower relaxation in arteries from diabetic rabbits),
indicate a decreased sensitivity to NO in the smooth muscle
cells of the basilar diabetic arteries. Therefore, these find-
ings suggest that diabetes alters the endothelial NO mod-
ulation of the endothelin-1-induced contraction in basilar
arteries by a mechanism that includes, at least, a decreased
sensitivity to NO in the vascular smooth muscle cells. This
fact could contribute to the hyperreactivity to endothelin-1
observed in the present work. Interestingly, this decreased
sensitivity to NO of diabetic basilar arteries cannot be
generalised to other vascular beds. We have previously
reported that, in renal arteries from diabetic rabbits, the
sensitivity of smooth muscle cells to NO is not altered
(Alabadı´ et al., 2001).
The participation of the arachidonic acid derivatives in
the modulation of the response of the basilar artery to
endothelin-1 was analysed by obtaining concentration–
response curves for this peptide in the presence of indo-
methacin, an inhibitor of the enzyme cyclooxygenase. Our
results show that incubation of basilar arteries from both
control and diabetic rabbits with indomethacin did not
significantly modify the endothelin-1-induced contraction,
suggesting that in rabbit basilar arteries, the endothelin-1-
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derivatives.
Vascular actions of endothelin-1 are primarily mediated
by two distinct G-protein-coupled receptor subtypes named
endothelin ETA and ETB receptors (Hopfner and Gopalak-
rishnan, 1999). Both endothelin ETA and ETB receptors are
located in the smooth muscle cells and mediate vasocon-
striction. Endothelin ETB receptors are also located in the
endothelium and mediate vasodilation through the activation
of NO release. In the present work, incubation with the
antagonist of the endothelin ETA receptors, BQ-123,
inhibited the contractile response of the basilar artery to
endothelin-1, in both control and diabetic rabbits. These
results confirm that the contraction of the rabbit basilar artery
in response to endothelin-1 is mediated by endothelin ETA
receptors. The fact that differences in the arterial response to
endothelin-1 between control and diabetic rabbits do not
persist after incubation with BQ-123 suggests a greater
participation of endothelin ETA receptors in diabetes, which
could contribute to the hyperreactivity to endothelin-1 ob-
served in diabetic animals. A recent study performed in vivo
shows that the activity of endogenous endothelin-1 on
endothelin ETA receptors is enhanced at the time that
sensitivity to exogenous endothelin-1 is blunted in the
resistance vessels of patients with type II diabetes (Cardillo
et al., 2002). Moreover, diabetes induces upregulation of
endothelin ETA receptors in rat heart (Chen et al., 2000).
In control rabbits, incubation of unrubbed arteries with
the antagonist of the endothelin ETB receptors, BQ-788,
enhanced the contractile response to endothelin-1. This
result suggests the participation of endothelial endothelin
ETB receptors mediating vasodilatation in the response of
basilar artery to endothelin-1. The presence of endothelin
ETB receptors that mediate endothelium-dependent relaxa-
tion in the rabbit basilar artery has been demonstrated
previously (Zuccarello et al., 1998). Therefore, we can
conclude that in rabbit basilar artery, endothelin-1 acts on
the endothelial endothelin ETB receptors, stimulating NO
release which in turn counteracts the vasoconstrictor action
of the peptide. In contrast, in diabetic rabbits, incubation of
unrubbed arteries with BQ-788 did not modify the maximal
contraction induced by endothelin-1. This result indicates
that diabetes impairs the vasodilator action of endothelin-1
mediated by NO release through endothelial endothelin ETB
receptor activation, and could explain the lower modulatory
role of the endothelium in the diabetic state described in the
present work. In renal perfusates of diabetic rats, the
impaired NO release in response to stimulation of endothe-
lin ETB receptors is attributed, at least in part, to a decrease
in the number or the activity of endothelial endothelin ETB
receptors (Kakoki et al., 1999). The impaired activity of
endothelin ETB receptors could contribute to the hyperre-
activity to endothelin-1 observed in diabetes.
In addition, our results show that in both control and
diabetic rabbits, incubation of rubbed arteries with BQ-788
displaced to the right the concentration–response curve toendothelin-1 with respect to the curves obtained with
untreated rubbed arteries. This result suggests that endothe-
lin-1 also acts on endothelin ETB receptors located on the
vascular smooth muscle that mediate vasoconstriction. The
fact that differences in the response to endothelin-1 in
rubbed arteries between control and diabetic rabbits (higher
potency in diabetes) do not persist after incubation of
rubbed arteries with BQ-788 (higher potency in control),
suggests a greater participation of muscular endothelin ETB
receptors in diabetes, which could also contribute to the
hyperreactivity of the basilar artery to endothelin-1 in
diabetes. This could be consistent with upregulation of
endothelin ETB receptors reported for the heart of diabetic
rats (Chen et al., 2000).
In summary, diabetes induces hyperreactivity of rabbit
basilar artery to endothelin-1. At least three causes could
contribute to this hyperreactivity: (1) the lower endothelial
inhibitory modulation of this response, including impaired
activity of the endothelial endothelin ETB receptors; (2)
lower sensitivity to NO in the vascular smooth muscle cells;
and (3) the greater participation of muscular endothelin ETA
and ETB receptors that mediate vasoconstriction. The cere-
brovascular bed hyperreactivity to endothelin-1 could con-
tribute to the greater susceptibility to cerebrovascular
diseases of diabetic patients.Acknowledgements
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